Modality
Bispecific Ab
MOA
CAR-T CD19
Target
AuroraA
Pathway
Wnt
MS
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
Aug 2021
→ Jun 2029
Phase 3Current
NCT05541528
503 pts·MS
2021-08→2029-06·Active
503 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-273.2y awayPh3 Readout· MS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Active
Catalysts
Ph3 Readout
2029-06-27 · 3.2y away
MS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05541528 | Phase 3 | MS | Active | 503 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |